First Trust Advisors
SMMT icon

First Trust Advisors’s Summit Therapeutics SMMT Stock Holding History

First Trust Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,115
Closed -$492K – 2715
2025
Q4 		$492K Sell
28,115
-143,409
-84% -$2.7M ﹤0.01% 2343
2025
Q3 		$3.54M Buy
+171,524
New +$4.16M ﹤0.01% 1555
2024
Q4 		– Sell
-422,950
Closed -$9.26M – 2638
2024
Q3 		$9.26M Sell
422,950
-365,117
-46% -$5.11M 0.01% 1065
2024
Q2 		$6.15M Buy
+788,067
New +$4.26M 0.01% 1184
2024
Q1 		– Sell
-170,189
Closed -$444K – 2405
2023
Q4 		$444K Buy
+170,189
New +$350K ﹤0.01% 2171

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors's SMMT Position: Q1 2026 in Review

First Trust Advisors sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 28,115 shares — an estimated $492K sold.

First Trust Advisors first reported a position in SMMT in Q4 2023 and held it in 5 quarters. The position peaked at $9.26M in Q3 2024. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • First Trust Advisors reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • First Trust Advisors sold 28,115 Summit Therapeutics shares in Q1 2026, an estimated $492K.
  • First Trust Advisors first reported a position in Summit Therapeutics in Q4 2023 and held it in 5 quarters.
  • First Trust Advisors's Summit Therapeutics position peaked at $9.26M in Q3 2024.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on First Trust Advisors's 13F filing for Q1 2026, filed 13 May 2026.